Quest Diagnostics to Unveil Extensions to its Women's Health and Personalized Medicine Test Offerings at the 2011 AACC Annual Meeting and Clinical Lab Expo
MADISON, N.J., July 25, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced it will unveil extensions to its women's health and AccuType® pharmacogenetic test menus, give eight scientific presentations and host six scientific speakers during the American Association of Clinical Chemistry (AACC) annual meeting and Clinical Lab Expo, to be held in Atlanta, July 26-28, 2011 (Exhibit number 3130).
Spinal Muscular Atrophy Testing Now Available Broadly in the U.S.
The extensions to the company's women's health menu feature Athena Diagnostics' spinal muscular atrophy (SMA) testing menu, believed to be the most comprehensive in the diagnostics industry. The services, which include adult-carrier screening and pre- and post-natal disease assessment testing, are now nationally available for the first time to physicians, laboratory directors and other clients of Quest Diagnostics. The offerings also position Quest Diagnostics as the only national major laboratory to provide testing services to assess SMA disease severity based on Athena's analysis of the number of copies of an SMA-associated gene.
Athena Diagnostics, which Quest Diagnostics acquired in April 2011, is the leader in neurology diagnostics and a pioneer in SMA testing, which it has performed since 1996. Prior to the acquisition, select Quest Diagnostics' business units had offered Athena Diagnostics' SMA testing services in select regions only.
The SMA adult-carrier screening test detects a defective survival motor neuron (SMN) 1 gene, which determines an individual's risk of passing SMA to offspring. The pre- and post-natal disease assessment tests identify the number of copies of the SMN2 gene, which affects disease severity.